Hengrui Pharma(SH:600276) Dongguan Securities·2025-09-25 03:52Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation that the stock will outperform the market index by more than 15% in the next six months [8]. Core Insights - The company is accelerating its international expansion, having licensed its innovative drug SHR-A1811 to Glenmark Specialty for an upfront payment of $18 million, with potential milestone payments and sales royalties totaling up to $1.093 billion. This marks the second significant overseas licensing deal for the company within the month [5][6]. - The drug SHR-A1811 has been approved for use in treating adult patients with HER2-mutated non-small cell lung cancer (NSCLC) and is the first Chinese-developed antibody-drug conjugate approved for this indication. The company is also pursuing new indications for breast cancer treatment [5]. - The company is enhancing its R&D capabilities and integrating into the global innovation network by collaborating with multinational pharmaceutical companies and innovative startups, aiming to maximize product value through international partnerships [5]. Financial Summary - The company’s projected financials for 2024 to 2027 show a steady increase in total revenue, from 27,985 million yuan in 2024 to 42,378 million yuan in 2027. Net profit is expected to rise from 6,337 million yuan in 2024 to 9,629 million yuan in 2027, with EPS projected to grow from 0.95 yuan in 2024 to 1.45 yuan in 2027 [6]. - The company’s return on equity (ROE) stands at 7.88%, with a market capitalization of 465.334 billion yuan and a closing price of 70.11 yuan as of September 24, 2025 [3][5].